EUVIMEDEUVIMED entdecken
Crossref

Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis

Guanghui Xu, Minghao Zheng, Zhigang Wu, Tianlei Xie, Yuqin Li, Ganlin Hu, Shuting Fang, Jing Zhang, Wenli Diao, Wei Zhao, Hongqian Guo, Junlong Zhuang

Drug Resistance Updates · 2026-03 · 85 · 101343

DOI: 10.1016/j.drup.2025.101343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Guanghui Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Institute of Ur…. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Urinary Bladder Neoplasms, Benzamides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Science Fund for Distinguished Young Scholars of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic dysregulation is a significant factor contributing to cisplatin resistance in bladder cancer (BCa). Increasing studies indicated a synergistic effect of cisplatin and Entinostat, which is an FDA-approved histone deacetylases (HDAC) inhibitor, however, the underlying mechanisms of this effect remains unknown. Herein, the synergy of cisplatin and Entinostat was confirmed in BCa cells. Integrated RNA-seq and ATAC-seq analysis revealed that the combined regimen of cisplatin and Entinostat led to significant downregulation of platinum resistance and DNA damage repair-related pathways. We focused on the candidate gene dehydrogenase/reductase member 2 (DHRS2), and found that Entinostat counteracted cisplatin resistance via promoting histone H3K18 lactylation (H3K18la)-mediated DHRS2 upregulation and enhancing the nuclear translocation of DHRS2. DHRS2 downregulation promoted cisplatin resistance by upregulating aldo-keto reductase family 1 member C3 (AKR1C3), a key enzyme in androgen synthesis. Moreover, we validated a negative correlation between DHRS2 levels and AKR1C3 expression in clinical BCa samples. It was found that high DHRS2 and low AKR1C3 expression correlates with improved neoadjuvant chemotherapy (NAC) response. Furthermore, high DHRS2 predicts better survival specifically in male patients, indicating sex-specific androgen involvement. Overall, these findings elucidate the epigenetic mechanism underlying the cisplatin-sensitizing effect of Entinostat, and identifies the DHRS2-AKR1C3-androgen axis as a potential target, particularly for male patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDrug Resistance, NeoplasmUrinary Bladder NeoplasmsBenzamidesAldo-Keto Reductase Family 1 Member C3PyridinesHumansCell Line, TumorHistonesDrug SynergismAntineoplastic Combined Chemotherapy ProtocolsGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsMaleMiceAnimals

Stichwörter der Autor:innen

Bladder cancerEpigeneticsHDACHistone lactylationSex Differences

Substanzen

CisplatinBenzamidesAldo-Keto Reductase Family 1 Member C3entinostatAKR1C3 protein, humanHistonesPyridinesHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Institute of Urology, Nanjing University, Nanjing 210008, China.
  • Department of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China.
  • Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China.
  • Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Institute of Urology, Nanjing University, Nanjing 210008, China; Department of Urolog…
  • Department of Clinical Biochemistry, School of Laboratory Medicine, Chengdu Medical College, Chengdu 610050, China; Clinical Laboratory, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical Coll…
  • Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Institute of Urology, Nanjing University, Nanjing 210008, China. Electronic address:…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Science Fund for Distinguished Young Scholars of Jiangsu Province

Zitieren

APA

Xu, G., Zheng, M., Wu, Z., Xie, T., Li, Y., Hu, G., Fang, S., Zhang, J., Diao, W., Zhao, W., Guo, H., & Zhuang, J. (2026). Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis. Drug Resistance Updates, 85, 101343. https://doi.org/10.1016/j.drup.2025.101343

Vancouver

Xu G, Zheng M, Wu Z, Xie T, Li Y, Hu G, et al. Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis. Drug Resistance Updates. 2026;85:101343. doi:10.1016/j.drup.2025.101343

BibTeX
@article{Xu2026,
  author = {Xu, Guanghui and Zheng, Minghao and Wu, Zhigang and Xie, Tianlei and Li, Yuqin and Hu, Ganlin and Fang, Shuting and Zhang, Jing and Diao, Wenli and Zhao, Wei and Guo, Hongqian and Zhuang, Junlong},
  title = {Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {85},
  pages = {101343},
  doi = {10.1016/j.drup.2025.101343}
}
Kostenlos starten →